Lavipharm S.A
Lavipharm S.A. engages in the research, development, manufacturing, import, marketing, sale, and wholesaling of pharmaceutical, dermocosmetic, and healthcare products in Greece and internationally. The company offers pharmaceutical products for cardiology, chronic pain and oncology, central nervous system, respiratory system, gastrointestinal system, and urology; and over the counter (OTC) drugs,… Read more
Lavipharm S.A - Asset Resilience Ratio
Lavipharm S.A (LAVI) has an Asset Resilience Ratio of 0.00% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2023)
This chart shows how Lavipharm S.A's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Lavipharm S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €3.00K | 0.0% |
| Total Liquid Assets | €3.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Lavipharm S.A maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Lavipharm S.A Industry Peers by Asset Resilience Ratio
Compare Lavipharm S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medicon Hellas S.A.
AT:MEDIC |
Drug Manufacturers - Specialty & Generic | 32.11% |
|
Tsumura & Co
MU:TSUA |
Drug Manufacturers - Specialty & Generic | 0.14% |
Annual Asset Resilience Ratio for Lavipharm S.A (2017–2023)
The table below shows the annual Asset Resilience Ratio data for Lavipharm S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | €3.00K | €114.79 Million | -15.98pp |
| 2022-12-31 | 15.98% | €18.24 Million | €114.17 Million | +12.87pp |
| 2021-12-31 | 3.11% | €1.64 Million | €52.74 Million | -0.71pp |
| 2020-12-31 | 3.82% | €1.93 Million | €50.64 Million | +3.79pp |
| 2018-12-31 | 0.03% | €12.00K | €41.90 Million | -0.07pp |
| 2017-12-31 | 0.10% | €44.00K | €44.81 Million | -- |